AxoGen
AXGN | NASDAQ
$55.38
-$0.55 (-0.98%)
At close: Nov 16, 2026, 4:00 PM ET
$55.10
-$0.28 (-0.51%)
After-hours:
Nov 16, 2026, 7:44 PM ET
AxoGen Company Profile
Company profile explainedCompany Profile
AxoGen, Inc., along with its subsidiaries, specializes in creating and distributing medical devices for the surgical repair of injured or severed peripheral nerves. Their comprehensive product portfolio offers several innovative solutions. The Avance Nerve Graft is a ready-to-use, biologically active human nerve allograft designed to bridge gaps in severed nerves. This avoids the need for a second surgical site for tissue donation, thereby eliminating associated complications. For facilitating the gentle reconnection of severed peripheral nerves, the company offers the AxoGuard Nerve Connector, an extracellular matrix (ECM) derived from porcine submucosa. This same porcine submucosa ECM forms the basis of the AxoGuard Nerve Protector, which is utilized to encase and safeguard damaged peripheral nerves, supporting their reconstruction and preventing unwanted adhesions from surrounding soft tissues. Another ECM product, the AxoGuard Nerve Cap, isolates the nerve end from its environment to help mitigate the formation of painful neuromas. Furthermore, AxoGen provides the Avive Soft Tissue Membrane, a processed human umbilical cord membrane that functions as an absorbable covering for soft tissues, used to separate tissues within the surgical area. An additional tool available is the AxoTouch two-point discriminator, used for evaluating the density of nerve innervation on the skin's surface. These products are supplied to hospitals, surgery centers, and military medical facilities, catering to plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen's market reach extends across the United States, Canada, Germany, the United Kingdom, other European nations, South Korea, and internationally. The company's main operations are situated in Alachua, Florida.
Key Executives
| Name | Position |
|---|---|
| Michael D. Dale | President, Chief Executive Officer & Director |
| Jens Schroeder Kemp | Chief Marketing Officer |
| Lindsey Hartley | Chief Financial Officer |
| Craig A. Swandal | Senior Vice President of Operations |
| Doris Quackenbush | Chief Revenue Officer |
| Erick DeVinney | Chief Scientific Officer |
| Harold D. Tamayo | Vice President of Finance & Investor Relations |
| Ivica Ducic | Chief Medical Officer |
| Marc A. Began | Executive VP, General Counsel, Secretary & Chief Compliance Officer |
| Rick Ditto | Vice President of Global Health Economics, Reimbursement & Policy |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 28, 2026 | 10-Q | Quarterly Report |
| Oct 28, 2026 | 8-K | Current Report |
| Oct 02, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Oct 01, 2026 | 8-K | Current Report |
| Sep 10, 2026 | 424B5 | Filing |
| Sep 10, 2026 | 8-K/A | [Amend] Current Report |
| Sep 10, 2026 | 8-K | Current Report |
| Sep 04, 2026 | 4 | Filing |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 12, 2026 | 4 | Filing |
AxoGen
| Country | United States |
| IPO Date | Dec 17, 1986 |
| Industry | Medical - Devices |
| Sector | Healthcare |
| Employees | 622 |
| CEO | Michael D. Dale |
Contact Details
13631 Progress Boulevard Alachua,
Florida 32615 United States
Stock Details
| Ticker Symbol | AXGN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000805928 |
| CUSIP Number | 05463X106 |
| ISIN Number | US05463X1063 |
| SIC Code | 3845 |
Recent News
- 9 hours ago / fool.comAxoGen: 3 Key Takeaways for Long-Term Investors
- 4 days ago / zacks.comAxoGen (AXGN) is a Great Momentum Stock: Should You Buy?
- 7 days ago / seekingalpha.comAxogen, Inc. (AXGN) Discusses Prostate Nerve Reconstruction Market Development Transcript
- 14 days ago / globenewswire.comAxogen, Inc. to Participate in Multiple Upcoming Investor Conferences
- 18 days ago / seekingalpha.comAxogen: Taking The Friction Out Of Nerve Repair
- 19 days ago / zacks.comIs AxoGen (AXGN) Outperforming Other Medical Stocks This Year?
- 19 days ago / marketbeat.comAxoGen Q3 Earnings Call Highlights
- 20 days ago / seekingalpha.comAxogen, Inc. (AXGN) Q3 2026 Earnings Call Transcript
- 20 days ago / zacks.comAxoGen (AXGN) Beats Q3 Earnings and Revenue Estimates
- 20 days ago / globenewswire.comAxogen, Inc. Reports Third Quarter 2026 Financial Results
Add to Watchlist
Select watchlists to add or remove AXGN